Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 Next >
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers ILMN MYGN
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers GSK MYGN PSNL QGEN
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.